C-ENNZTornado Therapeutics
rapalogs, mTOR inhibition
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-ENNZ
C-ENNZC-ENNZrapalogs, mTOR inhibition
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Extending the human lifespan: For preventing aging, some decades old drugs? | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's G
Licensing Deals in Biotechnology 2020-2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4311 EUR $4,799 USD £3,730 GBP This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user … ng Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Preclinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferen … iotech collaborations. At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements. This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, op … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? (Upfronts, milestones, royalties) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge - explore the report to … ical Biomedical Advanced Research and Development Authority Biomedical Catalyst Fund (UK) Biomica Biomunex Pharmaceuticals Bionaut Labs Biond Biologics BiondVax Bionomics BioNova Pharmaceuticals BioNTech BioNxt Solutions Bioprojet Biose Industrie Biosion Biosplice Biotheus Biotools BioVaxys Bioventure MDC BioVersys BioVie BIRAD Research and Development Company Bird Foundation Blacksmith Medicines Blackstone Medical Blau Pharma Bloom Science Bluebird Bio BlueJay Therapeutics B … apeutics Crohn's and Colitis Foundation of America Crown Bioscience CRT Pioneer Fund CryoPort CSIRO CSL CSL Behring CSPC Megalith Biopharmaceutical CSPC Pharmaceutical Group CStone Pharmaceuticals CTMC Cue Biopharma Cullinan MICA Cullinan Oncology Curacle Curative Biotechnology Cure Network Dolby Acceleration Partners CureVac Curia Curigin Curis
Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2026 | Current Partnering The store will not work correctly when cookies are disabled. JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser. My Account My Wish List Sign In Compare Products Create an Account Skip to Content Toggle Nav My Cart Search Search Search Menu Home CP Reports Store Industry sector reports Deal type reports Stage partnered reports Technology reports Therapy reports Subscription services Market forecast reports Curren … iotech collaborations. At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements. This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? ( Upfronts, milestones, royalties ) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge—explore the report to … al, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), Biomica, Biomunex Pharmaceuticals, Bionaut Labs, Biond Biologics, BiondVax, Bionomics, BioNova Pharmaceuticals, BioNTech, BioNxt Solutions, Bioprojet, Biose Industrie, Biosion, Biosplice, Biotheus, Biotools, BioVaxys, Bioventure MDC, BioVersys, BioVie, BIRAD Research and Development Company, Bird Foundation, Blacksmith Medicines, Blackstone Medical, Blau Pharma, Bloom Science, Bluebird … utics, Crohn's and Colitis Foundation of America, Crown Bioscience, CRT Pioneer Fund, CryoPort, CSIRO, CSL, CSL Behring, CSPC Megalith Biopharmaceutical, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CTMC, Cue Biopharma, Cullinan MICA, Cullinan Oncology, Curacle, Curative Biotechnology, Cure Network Dolby Acceleration Partners, CureVac, Curi
Licensing Deals in Biotechnology 2020-2026 - Research and Markets Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferences & Training Subscription … rvice CRADA Cross-licensing Development Distribution Equity purchase Evaluation Grant Joint venture Licensing Loan Manufacturing Marketing Option Promotion Research Royalty financing Settlement Spin out Sub license Supply Termination Warrant Every deal record is fully categorized and includes the following data, where available: Industry sector Therapy areas Technology type Deal components Financial terms Stage of development Exclusivity Asset type Geographic focus Excluded g … Forecasts, Till 2035 - Distribution by Source of Cell Line / Expression System, Application of Cell Line, Company Size, and Key Geographical Regions  Report 455 Pages December 2025 Global From €4311 EUR $4,799 USD £3,730 GBP This product is a market research report. Each license type allows a set number of users to access the report. Please select an option from the list below. This product is a market research report. This is a single user license, allowing one user … ng Deals in Biotechnology 2020-2026 close close ASK A QUESTION RESERVE MY PLACE Submit the form to confirm your enrolment and receive payment instructions. An error occurred while sending the message. Should this issue persist, email us at [email protected] * Required Information Name * Mr Mrs Dr Miss Ms Prof { }..." data-val-regex-pattern="^[^<>{}]*$" data-val-required="First Name field is required!" id="ProductEnquiry_FirstName" maxlength="50" name="ProductEnqu
Preclinical Stage Partnering Terms and Agreements in Pharmaceuticals and Biotechnology 2020-2026 Your browser is not supported. To avoid security issues and to comply with web standards, please upgrade to a modern browser. ABOUT US CONTACT US FAQ  USD EUR GBP USD ▼ USD EUR GBP € EUR $ USD £ GBP +353-1-416-8900 REST OF WORLD +44-20-3973-8888 REST OF WORLD 1-917-300-0470 EAST COAST U.S 1-800-526-8630 U.S. (TOLL FREE)  Login / Register Contact Us About Us View Categories Our Services Our Services Back Market Research Custom Research Conferen … iotech collaborations. At the preclinical stage, licensing agreements typically grant the licensee exclusive rights or options to develop a licensor's drug candidate or technology. These agreements are often multifaceted, beginning with collaborative R&D efforts and potentially culminating in commercialization agreements. This report provides detailed intelligence on the latest preclinical-stage agreements in the healthcare sector, helping companies evaluate market trends, op … as: What specific rights are granted in each agreement? What exclusivity terms apply? How is the deal structured financially? (Upfronts, milestones, royalties) Who controls development, manufacturing, and commercialization? How are intellectual property rights handled? What are the termination conditions for the agreement? What dispute resolution mechanisms are in place? How are confidentiality and publication rights managed? Gain the competitive edge - explore the report to … ical Biomedical Advanced Research and Development Authority Biomedical Catalyst Fund (UK) Biomica Biomunex Pharmaceuticals Bionaut Labs Biond Biologics BiondVax Bionomics BioNova Pharmaceuticals BioNTech BioNxt Solutions Bioprojet Biose Industrie Biosion Biosplice Biotheus Biotools BioVaxys Bioventure MDC BioVersys BioVie BIRAD Research and Development Company Bird Foundation Blacksmith Medicines Blackstone Medical Blau Pharma Bloom Science Bluebird Bio BlueJay Therapeutics B … apeutics Crohn's and Colitis Foundation of America Crown Bioscience CRT Pioneer Fund CryoPort CSIRO CSL CSL Behring CSPC Megalith Biopharmaceutical CSPC Pharmaceutical Group CStone Pharmaceuticals CTMC Cue Biopharma Cullinan MICA Cullinan Oncology Curacle Curative Biotechnology Cure Network Dolby Acceleration Partners CureVac Curia Curigin Curis
Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity | Aging Submit an Article Navigate Home Editorial Board Editorial Policies Current Volume Archive Scientific Integrity Publication Ethics Statements Interviews with Outstanding Authors Newsroom Sponsored Conferences Podcast Contact Special Collections Submit an Article Online ISSN: 1945-4589 Navigate Home Editorial Board Editorial Policies Current Volume Archive Scientific Integrity Publication Ethics Statements Interviews with Outstanding Authors Newsroom Sponsored Conferences Podcast … ific Meeting of the BSRA NOVA 2026 Recap Longevity & Aging Series 2025 EPIC Award Winner: Longevity & Aging Series Research Paper | Volume 16, Issue 20 | pp 12955 —12976 Longevity biotechnology: bridging AI, biomarkers, geroscience and clinical applications for healthy longevity Yu-Xuan Lyu 1 , Institute of Advanced Biotechnology and School of Medicine, Southern University of Science and Technology, Shenzhen, China 2 Max Planck Institute for Biology of Ageing, Cologne … University Medical Center, Rostock, Germany , Asif Bhatti 22 America's Frontier Fund, VA 23320, USA , Benjamin Yaden 23 Department of Biology, School of Science, Center for Developmental and Regenerative Biology, Indiana University - Purdue University Indianapolis, Indianapolis Indiana 46077, USA , Bente Klarlund Pedersen 24 Centre for Physical Activity Research, Rigshospitalet and University of Copenhagen, Denmark , Björn Schumacher 25 Institute for Genome Stability in … ales, Sydney, New South Wales, Australia , Mark Hamalainen 87 Longevity Biotech Fellowship, Longevity Acceleration Fund, Vitalism, SF Bay, CA 94101, USA , Maximilian Unfried 14 , Healthy Longevity Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 88 Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117608, Singapore , Michael S. Ringel 89 Boston Consulting Group, … Biochemistry of the Romanian Academy, Bucharest, Romania 22 America's Frontier Fund, VA 23320, USA 23 Department of Biology, School of Science, Center for Developmental and Regenerative Biology, Indiana University - Purdue University Indianapolis, Indianapolis Indiana 46077, USA 24 Centre for Physical Activity Research, Rigshospitalet and Univer
Multi-Disciplinary Program Hones Biomedical Commercialization Skills for Early-Career Scientists, Clinicians and Business Students | Enterprise Innovation Skip to main content Enter the terms you wish to search for. Select Search Option This Site All WCM Sites Directory Menu Weill Cornell Medicine Care Discover Teach I am interested in... Wayfinder menu News and Events Directory Cornell University Center for Technology Licensing Enterprise Innovation Explore this Website I am interested in... Wayfinder menu News and Events Directory Cornell University Center for Technology Licensing Home About … ovators menu options Learn About Our Process Connect with Enterprise Innovation Submit Disclosure to Center for Technology Licensing Material Transfer Agreements Inventor Portal Forms and Policies For Industry, Investors and Partners Toggle For Industry, Investors and Partners menu options Technology Portfolio Collaboration Opportunities About Our Startups Toggle About Our Startups menu options Our Startups Innovation Ecosystem Toggle Innovation Ecosystem menu options BioVent … sking, Gap and Seed Funding Sources menu options Enterprise Innovation Catalyst Fund Ignite Cornell Lab to Market SBIR/STTR Grant Writing Resources The Gene ’70, MD ’74 and Susan Resnick Prize for Excellence in Entrepreneurship Research and Industry Collaboration Opportunities Medical Device Initiatives Toggle Medical Device Initiatives menu options 3D Printer Interest Group Computation and Medical Device Interest Group General and Special Interests Toggle General and Special … gan Phung and Laura Eibler. Jeannie Carreiro is not present in photo. The three prize-winning teams addressed diseases that affect a large population. Tornado Therapeutics, whose name stands for twister optimized RNA for durable overexpression, won first place. Their innovation is a delivery platform technology that generates circular mRNAs and expresses them in virus-like particles (VLPs). With this platform technology, the team proposed developing a norovirus vaccine target … a (Chun-Ruei) Chyu and Margaret Hoang are not present in photo. The third-place prize went to VisionPro, a company that is developing a portable, quantitative imaging machine that enables accurate diagnosis and management of myopia (nearsightedness). VisionPro’s point-of-care device uses high-frequency ultrasound to track the changes in a patient
%PDF-1.7 %���� 8 0 obj > endobj xref 8 74 0000000016 00000 n 0000002091 00000 n 0000002214 00000 n 0000003631 00000 n 0000003656 00000 n 0000003792 00000 n 0000004280 00000 n 0000005058 00000 n 0000005492 00000 n 0000005527 00000 n 0000005571 00000 n 0000010568 00000 n 0000014310 00000 n 0000019826 00000 n 0000020236 00000 n 0000020658 00000 n 0000024576 00000 n 0000024972 00000 n 0000025436 00000 n 0000030258 00000 n 0000030666 00000 n 0000030884 00000 n 0000031125 00000 n 0000031525 00000 n 0000031879 00000 n 0000032120 00000 n 0000032520 00000 n 0000038227 00000 n 0000038466 00000 n 0000038 … #���3�.?n ��� F�u��f���p% Ɖf�]l��� ��bâg�]�Z~T�z� > endobj 65 0 obj >stream application/pdf Figure 2_v2 Adobe Illustrator 28.4 (Windows) 2024-09-18T14:39:27+01:00 2024-09-18T14:39:27+01:00 2024-09-18T14:39:27+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:318bdc18-360c-415d-8bf1-69c1a7997f03 uuid:b1c12e52-547e-43d5-a059-2c1963a9b22a uuid:9cca73b0-eaaa-4ccf-9565-1d61a2de99ee xmp.did:48dc9005-70af-dc43-b79c-f9b05dcb1859 uuid:65E6390686CF11DBA6E2D887CEACB407 p … be PDF library 17.00 21.0.0 endstream endobj 66 0 obj > endobj 67 0 obj >stream application/pdf Summary Adobe Illustrator 28.7 (Windows) 2024-09-10T14:53:01+01:00 2024-09-10T14:53:04+01:00 2024-09-10T14:53:04+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:d88f7321-ad7a-2a49-9a9f-a51a6febdd7c uuid:67bf6330-a9ad-466b-9369-19703334a416 uuid:dc9132fc-7149-41b9-94be-4ac9eeec17cc xmp.did:f2e350b5-6e08-1d47-a44d-34b9df711893 uuid:65E6390686CF11DBA6E2D887CEACB407 defau … be PDF library 17.00 21.0.0 endstream endobj 68 0 obj > endobj 69 0 obj >stream application/pdf Figure 1_v2 Adobe Illustrator 28.6 (Macintosh) 2024-09-03T16:36:21+01:00 2024-09-03T16:36:22+01:00 2024-09-03T16:36:22+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:9dd427ad-199a-4213-a992-2c01f2f9d538 uuid:822c90e0-1870-fe47-bce2-b6e7564cdff2 uuid:4532514a-8750-41e4-8820-7dbed4719c58 xmp.did:2a3aa489-5d6a-d34d-9ee1-a2e340adb7a6 uuid:65E6390686CF11DBA6E2D887CEACB407 … be PDF library 17.00 21.0.0 endstream endobj 70 0 obj > endobj 71 0 obj >stream application/pdf Figure 1_v2 Adobe Illustrator 28.6 (Macintosh) 2024-09-03T16:36:21+01:00 2024-09-03T16:36:22+01:00 2024-09-03T16:36:22+01:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:9dd427ad-199a-4213-a992-2c01f2f9d538 uuid:822c90e0-1870-fe47-bce2-b6e75
Federal Register, Volume 89 Issue 245 (Friday, December 20, 2024) [Federal Register Volume 89, Number 245 (Friday, December 20, 2024)] [Notices] [Pages 104208-104209] From the Federal Register Online via the Government Publishing Office [ www.gpo.gov ] [FR Doc No: 2024-30403] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Antitrust Division Notice Pursuant to the National Cooperative Research and Production Act of 1993--Rapid Response Partnership Vehicle Notice is hereby given that, on October 3, 2024, pursuant to section 6(a) of the National Coop … ity of New Jersey, Piscataway, NJ; The Administrators of the Tulane Educational Fund, New Orleans, LA; Verisim Life, Inc., San Francisco, CA; Arcturus Therapeutics Holdings, Inc., San Diego, CA; Blu Zone Bioscience & Supply Chain Solutions, LLC, Frederick, MD; Elligo Health Research, Inc., Austin, TX; Guide Biomedical Solutions, LLC, Media, PA; Integral Molecular, Philadelphia, PA; Komo Biosciences, Inc., Newton, MA; P95, BV, Leuven, BELGIUM; Southwest Research Institute, San
Altos Labs About About Science Careers Careers Featured Contact About / Executive Leadership Joan Mannick, MD SVP, Chief Medical Officer and Head of Product Development SVP, Chief Medical Officer and Head of Product Development " Altos has gathered together some of the world’s greatest scientists to discover ways to reverse disease. That is an incredibly ambitious and exciting mission that will change the practice of medicine. I am thrilled to be able to help bring this groundbreaking science to patients. " Dr. Joan Mannick is the Senior Vice President, Chief Medical Officer and Hea
Pharmas and biotechs are investing in new treatments for diseases of aging Discover Clarivate search Support Investors Careers Login Clarivate Corporate Clarivate for Academia & Government Clarivate for Life Sciences & Healthcare Clarivate for Intellectual Property Life Sciences & Healthcare Main Menu Products and services Life Sciences & Healthcare Deliver safe, effective and commercially successful treatments to patients faster. Confidently make smart, patient-centric decisions and navigate roadblocks with the help of AI-powered intelligence platforms that are fueled by ext … The machine-readable files are formatted to allow researchers, regulators, and application developers to more easily access and analyze data. View now north_east
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Press Release: Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award @ Cambrian Biopharma | Future Ventures Job Board Home Team News Investments Connect Home Team News Investments Jobs Connect Be the Future. Future Ventures is more than a name for us. We invest in companies that emphasize sustainability, innovation, and inclusive culture. Join us in our mission to make an impact on future generations. companies Jobs Search jobs Explore companies Join talent network Talent My job alerts Press Release: Cambrian Bio Named an Honoree of Fast Company's Next Big Thi … e: Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award Cambrian Biopharma This job is no longer accepting applications See open jobs at Cambrian Biopharma . See open jobs similar to " Press Release: Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award " Future Ventures . Posted 6+ months ago NEW YORK, Dec. 5, 2023 -- Cambrian Bio, a New York-based clinical-stage drug development company, is among the honor … he honorees for Fast Company's Next Big Things in Tech 2023. The purpose of the award is to celebrate technological breakthroughs that are changing the way we live. Founded in 2019 by James Peyer, PhD., Cambrian develops therapeutics targeting key biological pathways that decline or malfunction with age to create medicines that have the potential to treat and prevent some of today's most debilitating diseases. Each program is launched within Cambrian in collaboration with t … e: Cambrian Bio Named an Honoree of Fast Company's Next Big Things in Tech Award " Future Ventures . See more open positions at Cambrian Biopharma Powered by Getro.com Privacy policy Cookie policy Privacy Policy Future Ventures Reg. U.S. Pat. & Tm. Off.
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Jobs at Cambrian Biopharma | Consider You are using an outdated browser. Please upgrade your browser to improve your experience and security. Home Sign In Powered by Consider Privacy Terms
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Enhanced Group registers 61.7M shares for resale | APAD Prospectus Summary --> STOCK TITAN Login Sign up Login Sign up 0 HOME --> NEWS FEED Stock News Live Stock News Today Trending News AI news FDA Approvals Clinical Trials Crypto News Merger & Acquisitions Earnings Offerings IPO News Stock Splits Top News - Gainers Top News - Losers SEC FILINGS SEC Filings Live SEC Filings Today Form 4 - Insider Trading 8-K - Material Events 10-K - Annual Reports 10-Q - Quarterly Reports DEF 14A - Proxy Statements S-1 - IPO Registration S-3 - Shelf Registration STOCKS All Stock Themes AI Stocks Crypto Stocks … it can alter which laws, tax rules, reporting standards and shareholder rights apply, potentially affecting costs, governance and the value or liquidity of the company’s shares. Sponsor Equity Agreement financial "Apeiron and the Sponsor entered into the Sponsor Equity Agreement" Registration statement on Form S-1 (shelf) regulatory "registration statement on Form S-1 that we filed with the SEC using the “shelf” registration process" See more from StockTitan in Google Search … 026, as contemplated by the Business Combination Agreement, A Paradise filed an application to discontinue as a business company with the BVI Registrar of Corporate Affairs, together with the necessary accompanying documents, and filed a certificate of formation and a certificate of conversion of a foreign entity converting to a Texas filing entity with the Secretary of State of the State of Texas, under which A Paradise domesticated and continued as a Texas corporation. On M … me, upon substantially the same terms and conditions as were applicable to such award immedia tely prior to the First Effective Time; • “Enhanced Holder Support Agreement” are to that certain Company Holder Support Agreement, dated November 26, 2025, entered into by and among A Paradise, Enhanced and the Major Enhanced Shareholders, a copy of which is filed as Exhibit 10.16 to the registration statement of which this prospectus forms a part; vi Table … gment, determination, Governmental Order, writ, injunction, decree, arbitration award, treaty, agency requirement, authorization, license or permit of any governmental authority and “laws” are to two or more of the foregoing, or all such laws collectively, as the context requires; • “Letter Agreement” are to the
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Speakers | ARDD 2022 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 Photos 2022 Vi … al Society of America and American Federation for Aging Research, the Longevity prize from the IPSEN Foundation, and the first international Olav Thon Foundation prize. She is an elected fellow of the American Association for the Advancement of Science, American Association for Cancer Research, and the National Academy of Sciences. She serves on numerous national and international editorial and scientific advisory boards. Johan Auwerx Professor at the Ecole Polytechnique Fédé … nt director at Apollo Health Ventures, a biotech company builder and investment fund focused on targeting chronic age-related diseases. At Apollo, Alexandra is leading the venture creation programs, while also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical stage biotech companies. Before joining Apollo, Alexandra worked with The Boston Consulting Group where she specialized in biopharma strategy. Alexan … C, graduated from Dresden Medical School (Germany), Swiss board certified after residency and fellowship at the University Hospitals of Zurich and Basel (Switzerland). Published over 80 peer-reviewed papers, frequent speaker at scientific and medical conferences in Asia and Europe. Long term member of various medical societies, e.g. European Federation of Internal Medicine, World Academy of Medical Sciences, Swiss Society of Internal Medicine etcc. Spent a decade practicing m … at the Buck Institute for Research on Aging, and a K99 Pathway to Independence award to study inter-organ signaling in aging. Michael Ben Ezra University of Copenhagen, Denmark Joanna Bensz Founder and CEO, Longevity Center, Europe Longevity Center is part of the Longevity Group SA, an investment company based in Luxemburg creating an ecosystem
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
What Is A Longevity Biotechnology Company? Sign Up For Newsletters Games Share a News Tip Featured Featured Breaking News White House Watch Daily Cover Stories Making It Their Way: Six TikTok Creators On Finding A High-Quality Content Strategy That Pays Off | Paid Program The Hidden Tax On Enterprise AI: 1 In 5 Workers Lose A Full Day Every Week | Paid Program Silicon & Steel Editorial Video Series Turning Pressure Into Progress For Your Small Business | Paid Program Uniting To Advance Blood Cancer Research | Paid Program The Enterprise AI Shortcut: Why Co-Innovation Is Setting A New Speed … scence, Life Biosciences, Longevity Biotechnology Association, Longevity Vision Fund, Lygenesis, Oviva Therapeutics, Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School, Rejuveron, Retro Biosciences, and Tornado Therapeutics. Picture of the screen showing a research paper titled "Defining a longevity biotechnology company", Nature Biotechnology, June 2023 Alex Zhavoronkov, PhD This perspective paper underscores the importance of defining lon … vides additional insights, emphasizing that investors should consider "the application of the technology to a clear disease indication today, allowing the medicine to reach the market after being tested for safety and efficacy, and the ability of the intervention to not only treat but also prevent disease." As the longevity biotechnology landscape continues to expand, it's crucial for stakeholders, from investors to researchers, to have a clear understanding of
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Is aging without illness possible? Skip to content Subscribe today Every print subscription comes with full digital access Subscribe Now Menu All Topics Health Humans Anthropology Health & Medicine Archaeology Psychology View All Life Animals Plants Ecosystems Paleontology Neuroscience Genetics Microbes View All Earth Agriculture Climate Oceans Environment View All Physics Materials Science Quantum Physics Particle Physics View All Space Astronomy Planetary Science Cosmology View All Magazine Menu All Stories Multimedia Reviews Puzzles Collections Educator Portal Century of Science Unsung … which holds competitions to spur technological developments and announced a new prize related to aging in November. “We are a lot less dead than we used to be because of where public health and modern medicine has gotten us.” There’s a downside, of course. We’re living long enough to see the frailty and illness that comes with old age. Cells stop dividing, DNA degrades, the immune system falters. We become increasingly vulnerable to disease. Many of us spend our last decades … ng the field together. He landed on geroscience , a word he had first seen in a grant proposal by another researcher studying aging, Gordon Lithgow. “Gero-” comes from the Greek word for old man. It wasn’t difficult to convince other researchers to get on board. “Everybody listened to me because I was in charge of the money,” says Sierra, now chief scientific officer at Hevolution Foundation , a nonprofit that funds geroscience research. What compounds might fight aging? Thou
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Longevity Medicine Day| ARDD 2023 Main Past events ARDD 2025 ARDD 2024 XPRIZE Healthspan Team Summit 2024 ARDD 2023 ARDD 2022 About Speakers Speakers 2026 Speakers 2025 Speakers 2024 Speakers 2023 Speakers 2022 Program Main Track Longevity Medicine Track Emerging Science & Technologies Workshop Physics in Aging Biology Startup Pitch Replacement in Aging Workshop Molecular Nutrition Workshop ARDD Tracks Sponsorship Sponsorship Brochure Sponsors 2025 Sponsors 2024 Sponsors 2023 Sponsors 2022 Media Scam Warning Photos Videos Media Kit Photos 2025 Photos 2024 Photos 2023 P
Novartis - Wikipedia Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Contents move to sidebar hide (Top) 1 History Toggle History subsection 1.1 Ciba-Geigy 1.2 Mid-1990s controversy 1.3 Sandoz 1.4 Merger 1.5 Post-merger 1.5.1 2000–2010 1.5.2 2011–present 1.6 Acquisition history 2 Corporate structure 3 Place in its ma … . Dan Fagin 's Toms River: A Story of Science and Salvation , the 2014 Pulitzer Prize winning book, examined the issue of industrial pollution at the site in detail. Sandoz [ edit ] Main article: Sandoz The Sandoz brand exists today as a subsidiary of Novartis. Sandoz is the generic drugs division of Novartis. Before the 1996 merger with Ciba-Geigy to form Novartis, Sandoz Pharmaceuticals (Sandoz AG) was a pharmaceutical company headquartered in Basel , Switzerland (as was Ci … In 2013, the Indian Supreme Court issued a decision rejecting Novartis' patent application in India on the final form of Gleevec , Novartis's cancer drug; the case caused great controversy. [ 45 ] In 2013, Novartis was sued again by the US government, this time for allegedly bribing doctors for a decade so that their patients are steered towards the company's drugs. [ 46 ] In January 2014, Novartis announced plans to cut 500 jobs from its pharmaceuticals divi … of Chimeric antigen receptor T cell (CAR T cells). Finally, the deal "will also apply AI to generative chemistry to enhance drug design". [ 74 ] In November 2019, Sandoz announced it would acquire the Japanese business of Aspen Global inc for €300 million (around $330 million), boosting the business's presence in Asia. [ 75 ] In late November 2019, the business announced it would acquire The Medicines Company for US$9.7 billion ($85 per share) in ord … a, and took the case all the way to the Indian Supreme Court , where the patent application was finally rejected. The patent application at the center of the case was filed by Novartis in India in 1998, after India had agreed to enter the World Trade Organization and to abide by worldwide intellectual property standards under the TRIPS agreement.
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Members | Longevity Biotechnology Association About Members Collaborators News Contact Donate Our members make us Nir Barzilai Founding Director of the Institute for Aging Research at the Nathan Shock Center of Excellence in the Basic Biology of Aging. Director of the Paul F. Glenn Center for the Biology of Human Aging Research at Albert Einstein College of Medicine. Andre Bertram Co-Founder of Beyond Aging, an organization dedicated to growing the funding environment for longevity research, and CEO of Helpwear, a medical device company building emergency cardiac monitoring devices. Joe Betts- … Co-Founder & Managing Director at Apollo Health Ventures, a venture capital fund that invests in early-stage biotech and aging biology companies. Daisy Robinton Co-Founder and CEO of Oviva Therapeutics, Director of Women's Health at Cambrian Biopharma. Hillel Roth Scientist and entrepreneur whose scientific contributions include some of the most widely used tools for RNA editing. CSO and co-founder of Aevum Labs, a company founded to radically extend humanity’s healt … y lifespans of at least one billion people. Co-Founder of BOLD Longevity Growth Fund. Innovation Board Member at XPRIZE Foundation, Development Sponsor of the Healthspan XPRIZE. Alex Zhavoronkov Current Founder and CEO of Insilico Medicine, and founder and former CEO of Deep Longevity. Garri Zmudze Garri Zmudze is an investor and advisor for deeptech companies developing life-changing solutions across biotech, medicine, longevity and more. Garri is committed to building a wor
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Speakers - Hevolution Foundation Navigation Skip to Content About GHS Speakers Program Program day 1 Program day 2 Visitor Guidebook العربية Home Global Healthspan Summit 2025 Speakers --> 100+ Speakers Discover the leading minds that joined us for GHS 2023 Professor Raghib Ali OBE is the Chief Investigator, Interim CEO, and Chief Medical Officer of Our Future Health; a Clinical Epidemiologist at the University of Cambridge; a Consultant in Acute Medicine at the Oxford University Hospitals NHS Trust; and an Honorary Consultant with the Office for Health Disparities and Improvement. He gr … ll, Doctor Diz Pintado, Beug Foundation Metastasis, City of Barcelona, National Award, the Foundation Serra, the Severo Ochoa, and the Lilliane Bettencourt. He is an EMBO member and has received an Advanced ERC grant. SESSIONS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Dr. Salvador Aznar Benitah رئيس قسم الشيخوخة والتمثيل الغذائي Position: Head of Aging & Metabolism Depart … and data-driven health. Peter is Co-founder of BOLD Capital Partners, a venture fund with $500B under management investing in exponential technologies and longevity companies. He earned degrees in molecular genetics and aerospace engineering from MIT and holds an M.D. from Harvard Medical School. SESSIONS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Dr. Peter Diamandis Founder P … deration for Aging Research, and was the 2020 recipient of the Irving S. Wright Award of Distinction in Aging Research. SESSIONS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Day 01 | 9:00 A.M. - 10:00 A.M. CLOSING REMARKS Dr. James L. Kirkland Noaber Foundation Professor of Aging Research Position: Noaber Foundation Professor of Aging Research Organization: Mayo Clinic Country: United States MORE DETAIL … nvestment expertise managing PE & VC funds, Sergey founded Longevity Vision Fund (LVF) in 2019 to invest in leading biotech companies targeting the underlying causes of aging. LVF has grown its portfolio to 18 companies across gene therapies and editing, AI-enabled drug discovery, and early-stage diagnostics. LVF was honored as a World Changi
Past Events | Page 9 | Enterprise Innovation Skip to main content Enter the terms you wish to search for. Select Search Option This Site All WCM Sites Directory Menu Weill Cornell Medicine Care Discover Teach I am interested in... Wayfinder menu News and Events Directory Cornell University Center for Technology Licensing Enterprise Innovation Explore this Website I am interested in... Wayfinder menu News and Events Directory Cornell University Center for Technology Licensing Home About Us Toggle About Us menu options Leadership Team Directory Annual Reports Support Us For Inventors and Innovat … ovators menu options Learn About Our Process Connect with Enterprise Innovation Submit Disclosure to Center for Technology Licensing Material Transfer Agreements Inventor Portal Forms and Policies For Industry, Investors and Partners Toggle For Industry, Investors and Partners menu options Technology Portfolio Collaboration Opportunities About Our Startups Toggle About Our Startups menu options Our Startups Innovation Ecosystem Toggle Innovation Ecosystem menu options BioVent … sking, Gap and Seed Funding Sources menu options Enterprise Innovation Catalyst Fund Ignite Cornell Lab to Market SBIR/STTR Grant Writing Resources The Gene ’70, MD ’74 and Susan Resnick Prize for Excellence in Entrepreneurship Research and Industry Collaboration Opportunities Medical Device Initiatives Toggle Medical Device Initiatives menu options 3D Printer Interest Group Computation and Medical Device Interest Group General and Special Interests Toggle General and Special … nts NSF I-Corps Regional Course for Startups Hosted by University of Rochester (Application Deadline: 7/2/25) Wednesday, July 2, 2025 - 9:00am to 5:00pm Location: Virtual *For teams affiliated with business incubators. In this virtual course (held July 28 - August 27) , early-stage technology startup teams will learn how to conduct customer discovery interviews with potential customers, partners and industry stakeholders. The course goal is to gather evidence that your produc … need for your customers and make a large impact in your target market. You may apply with a team of 1-3 people. Teams may not split attendance between members. Please only include the members of your team that will be fully participating in the course. All team members are required to attend and participate fully in every course session and comp
DEF 14A 1 ny20007624x1_def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.) Filed by the Registrant ☒ ​ ​ Filed by a Party other than the Registrant   ☐ Check the appropriate box:   ☐ ​ ​ Preliminary Proxy Statement   ☐ ​ ​ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ ​ ​ Definitive Proxy Statem … This means that you can attend the Annual Meeting online, vote your shares and submit questions during the online meeting. We believe that hosting a “virtual meeting” will enable greater stockholder attendance and participation from any location around the world. You can find more information, including the nominees for director, in the attached proxy statement for the Annual Meeting. The board of directors recommends that you vote “FOR” each of the C … recommends that you vote “FOR” each of the Class II directors (Proposal 1) and “FOR” the ratification of the appointment of the proposed independent registered public accounting firm (Proposal 2) as outlined in the attached proxy statement. We are pleased to comply with the rules of the Securities and Exchange Commission that allow companies to distribute their proxy materials over the Internet under the “notice and access” approach. A … information about how to attend the Annual Meeting online, vote your shares and submit questions during the meeting is included in the accompanying proxy statement. Whether or not you plan to attend the Annual Meeting online, we urge you to take the time to vote your shares.   ​ ​ By Order of the Board of Directors,   ​ ​     ​ ​ Daniel J. Hicklin, President and Chief Executive Officer Watertown, MA April 27, 2023 T … T THE ANNUAL MEETING AND VOTING ​ ​ 2   ​ ​   PROPOSAL NO. 1-ELECTION OF THREE CLASS II DIRECTORS ​ ​ 6   ​ ​   PROPOSAL NO. 2-RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 202
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Cambrian Biopharma Announces Licensing Agreement Facebook Linkedin Twitter Industries Aerospace Agritech Automotive BFSI Biotechnology Chemicals Defence Technology Energy, Power and Sustainability Food & Beverage Healthcare Information Technology MarTech Internet Of Things (IOT) Logistics and Supply Chain Materials Medical Devices Retail Semiconductor & Electronics Smart Lighting Latest News Interviews Insights Guest Post Staff Writer Featured Article Quick Byte Resources Search Sunday, June 28, 2026 Facebook Linkedin Twitter Sign in Welcome! Log into your account your username your pa … from Harvard College and an M.D. from Harvard Medical School and completed her residency at Brigham and Women’s Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program. Tags Biotechnology Cambrian Biopharma Develop Healthcare Licensing Agreement New York news Read Magazine Selective mTOR Inhibitors Share Facebook Twitter Linkedin WhatsApp Previous article Curve Therapeutics Announces Collaboration with MSD for
News and Publications About Science Pipeline Team Careers News & Publications Blogs Contact News & Publications Cambrian Bio Presents Positive Human Translational Data for ATX-304, the First AMPK Network Activator, at the American Diabetes Association's 86th Scientific Sessions 10 mins to read 18 June 26 Cambrian Bio Presents Positive Human Translational Data for ATX-304, the First AMPK Network Activator, at the American Diabetes Association's 86th Scientific Sessions 18 June 26 10 mins to read min read Cambrian Bio to Present Two Posters on ATX-304 at the American Diabetes A … boosting Therapeutics to the Clinic Financing co-led by Anthos Capital and SALT Fund; Anthos’s Paul Farr and biotech leader Brent Saunders to join Board of Directors. See More Visit Previous 2 / 2 In the News Granata Bio 19 April 26 Granata Bio Expands Women's Health Portfolio with Acquisition of US-Based Oviva Therapeutics Granata Bio announced the acquisition of Oviva Therapeutics, Inc., a pioneering women's health biotech company focused on advancing treatments t … — and industry — are seeking to extend healthy lives.” As billionaires race to fund anti-aging projects, a much-discussed trial goes overlooked. Cambrian BioPharma CEO James Peyer weighs in on the TAME trial. Visit Endpoints News 20 May 22 A new spinout wades into ovarian aging, armed with a seed round and experimental drugs from Mass General Oviva Therapeutics, a pipeline company of New York-based Cambrian Biopharma, emerged from stealth to dive into the idea of extending w … oresight Institute Biotech & Health Extension Webinar: “James Peyer: How to Fund and Build Geroprotectors” In this session, James Peyer, PhD, CEO of Cambrian BioPharma, shares his overview of the longevity biotech industry with insights into what it actually means to be a longevity biotech company, how Cambrian functions, what is a "DisCo model" (and why it will most likely replace single asset biotech companies model), and the barriers preventing us from starti … ing the advantages of the standard biotech firm with those of a venture capital fund and biotech incubator, to establish a platform for the development of new anti-aging therapeutics. Visit Longevity Technology 11 February 21 Longevity.Technology: International Day of Women and Girls in Science In 2015, The UN declared February 11th the “Internat
Cambrian Bio | Blogs Insights and thought leadership from Cambrianites Filter by Cambrian Blog An Ounce of Longevity Executive Minded Show All Cambrian Blog 10 mins to read 16 January 24 An approach to evaluate therapeutics program quality Our Senior Ventures Director, Ethan Sarnoski, PhD., outlines his hypothesis-driven approach for evaluating the quality of any given therapeutics program as one component of the larger drivers of success for a company. See More Visit An Ounce of Longevity 5 mins to read 28 November 23 What If Metabolism Didn’t Have to Drop? Our VP of Global Policy and Strateg
Cambrian Biopharma – CAM-5131 Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance Cryptocurrency
Tornado Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse Products Data Feature Plans Request Demo Sign Up for Free Last update 04 Mar 2026 Tornado Therapeutics, Inc. Private Company | New York, United States | < 10 | www.tornado-tx.com Private Company | New York, United States | < 10 | www.tornado-tx.com Last update 04 Mar 2026 Overview Pipeline Deal Translational Medicine Profit Grant & Funding(NIH) Investment Financing Overview Tags Neoplasms Respiratory Diseases Infectious Diseases Small molecule drug Disease domain score A glimpse into the focused therapeut … itions of over 360K organizations with Synapse. login or view full example data Grant & Funding(NIH) Access more than 2 million grant and funding information to elevate your research journey. login or view full example data Investment Gain insights on the latest company investments from start-ups to established corporations. login or view full example data Financing Unearth financing trends to validate and advance investment opportunities. login or view full example data
Tornado Therapeutics - KED Global --> --> PharmaResearch acquires TuringBio for digital therapeutics PharmaResearch Co., a South Korean company specializing in regenerative medicine, announced on Wednesday that it acquired TuringBio, an AI-based dig... Korean biotech Xcell Therapeutics eyes June IPO South Korean biotech Xcell Therapeutics Inc., a developer of chemically defined media for in vitro cell culture, is aiming for a junior bourse Kosda... Samsung invests in BrickBio in US Samsung Group announced on Tuesday that its Life Science Fund has invested in the US-based antibody-drug conjugat … eutics on RT-111, an or... Korea’s big bio startups to launch $39 mn investment fund South Korea’s four leading biotech firms plan to launch an investment fund of up to 50 billion won ($39 million) to support smaller domestic b... HLB Therapeutics signs contract for COVID vaccine distribution rights South Korea's pharmaceutical firm HLB Therapeutics Co. said on Monday that it has signed an agreement with the Korea Disease Control and Prevention ... New drug developer On
Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors Accessibility Statement Skip Navigation Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact Search Search When typing in this field, a list of search results will appear and be automatically updated as you type. Searching for your content... No results found. Please change your search terms and try again. News in Focus Browse News Releases All News Releases All Public Company English-only News Releases Overview Multimedia Gallery All Multimedia All Photos All Vi … from Harvard College and an M.D. from Harvard Medical School and completed her residency at Brigham and Women's Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program. About mTOR Inhibitors The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). mTOR inhibitors are an exceptionally well-explored therapeutic class, encompassing three FDA-approved med … tform Login ProfNet Data Privacy Do not sell or share my personal information : Submit via [email protected] Call Privacy toll-free: 877-297-8921 Contact PR Newswire Products About My Services All News Releases Platform Login ProfNet Call PR Newswire at 888-776-0942 Terms of Use Privacy Policy Information Security Policy Site Map RSS Cookies Copyright © 2026 Cision US Inc. --> -->
BioCentury - Cambrian launches new subsidiary to develop mTOR inhibitors This Edition ARTICLE | Deals Cambrian launches new subsidiary to develop mTOR inhibitors Novartis deal gives Tornado Therapeutics assets for age-related diseases By Stephen Hansen, Associate Editor February 17, 2022 12:32 AM UTC Cambrian has added to its age-related disease portfolio via a deal with Novartis for a series of mTOR inhibitors that will be developed by newly launched subsidiary Tornado Therapeutics. Cambrian Biopharma Inc. acquired exclusive, worldwide rights to a group of selective mTOR inhibitors from Novar
Cambrian Bio About Science Pipeline Team Careers News & Publications Blogs Contact Back Copied! Press Release: Cambrian BioPharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors 5 mins to read February 16, 2022 Author: Cambrian BioPharma New York, Feb. 16, 2022 - Cambrian BioPharma, a multi-asset longevity biotech, announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by Novartis to target the mechanistic target of rapamycin (mTOR) pathway. The licensed assets are structural analogs of the FDA-approved drug rapamyc … from Harvard College and an M.D. from Harvard Medical School and completed her residency at Brigham and Women's Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program. About mTOR Inhibitors The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). mTOR inhibitors are an exceptionally well-explored therapeutic class, encompassing three FDA-approve
Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors - BioSpace News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy Cancer Opinions Press Releases All News & Releases Podcasts Events Jobs Companies Hotbeds More Reports Career Advice NextGen: Top Startups to Watch 40 Under 40 Best Places to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event SUBSCRIBE Menu SUBSCRIBE Show Search News Drug Development FDA Manufacturing Deals Business Job Trends Cell and Gene Therapy C … laces to Work Employer Resources Advertise Advertise Talent Solutions Post Jobs Submit a Press Release Submit an Event Search Query Submit Search News Business Cambrian Biopharma Announces Licensing Agreement to Develop Selective mTOR Inhibitors February 16, 2022 | 4 min read Twitter LinkedIn Facebook Email Print Cambrian Biopharma today announced a licensing agreement with Novartis to advance novel, selective compounds designed and characterized by … from Harvard College and an M.D. from Harvard Medical School and completed her residency at Brigham and Women's Hospital, followed by an infectious diseases fellowship as part of the Harvard Combined Infectious Diseases Program. About mTOR Inhibitors The FDA-approved drug rapamycin and its analogues (rapalogs) are inhibitors of the mechanistic target of rapamycin (mTOR). mTOR inhibitors are an exceptionally well-explored therapeutic class, encompassing three FDA-approved med … Policy RSS Feeds Advertise Employer Login Post Jobs Talent Solutions Advertise Submit a Press Release Submit an Event © 1985 - 2026 BioSpace.com. All rights reserved. twitter instagram facebook linkedin
Translating Aging | Castamatic CASTAMATIC Podcasters Blog Contact Translating Aging by BioAge Labs On Translating Aging, we talk with the worldwide community of researchers, entrepreneurs, and investors who are moving longevity science from the lab to the clinic. We bring you a commanding view of the entire field, in the words of the people and companies who are moving it forward today. The podcast is sponsored by BioAge labs, a clinical-stage biotechnology company developing therapies to extend human healthspan by targeting the molecular causes of aging. Visit website Open in Castamatic Get C
Cambrian Biopharma Announces Plan to Develop New mTOR Inhibitors, Tornado Therapeutics led by Joan Mannick - News - Rapamycin Longevity News Rapamycin Longevity News Cambrian Biopharma Announces Plan to Develop New mTOR Inhibitors, Tornado Therapeutics led by Joan Mannick News RapAdmin February 16, 2022, 5:05pm #1 This is big news… another major startup company working to develop rapamycin-like drugs, this time with Joan Mannick as the CEO of the company. This is yet another vote of confidence on rapamycin, and the MTOR pathway as being a key target for life extension. Joan Mannick has said th
Q2 2023 LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy . Skip to main content Lin … of 4D-150 Gene Therapy to Otsuka Dr. Timos Papagatsias 7mo $650M Life Sciences Fund, Longboard Stock Soars, Novartis/Voyager Partner & Pfizer Approval (Plus Some 2023 News!). Paula Doust Alba 2y Show more Show less Similar topics Biotech IPO Pipeline and R&D Challenges 3 Posts 215 Latest Trends in Biotech Innovations 10 Posts 1,493 TechBio Investment Strategies 5 Posts 997 Biotechnology Conference Highlights 10 Posts 977 Trends in Biotech for Oncology 10 Posts 1,155
A4LI 2025 D.C. Summit Recap - Alliance for Longevity Initiatives Skip to content Dylan V. Livingston and former Speaker Newt Gingrich Discuss Prioritization of Longevity Science Join A4LI Become a Member Become a Sponsor Get Involved Our Advocacy Publications Longevity Science Caucus Podcasts H-SPAN Podcast Scientific Spotlights About Events A4LI H-SPAN Summit D.C. Past Events A4LI Longevity Investors Summit A4LI 2025 D.C. Summit Recap DC Fly-In 2024 Geroscience Education Reception LogIn Join A4LI Become a Member Become a Sponsor Get Involved Our Advocacy Publications Longevity Science Caucus … etr Sramek MBA, Co-founder, Chairman and Managing/General Partner Longevitytech.fund Joan Mannick, MD Co-Founder and CEO Tornado Therapeutics Chris Bradley, MS Co-Founder and CEO Matter Bio Jasmine Smith CEO Rejuve.AI Christopher Steele Ph.D, CSO Medical Technology Enterprise Consortium (MTEC) Vera Gorbunova Ph.D, Professor University of Rochester Natalia Mitin Ph.D, Co-Founder and CEO Sapere Bio Dobri Kiprov MD, CMO Lifespan Edge Niklas Anzinger Co-Founder and CEO Infinita C … Brenda Eap, PhD Karl Pfleger, PhD Angel Investor Petr Sramek, MBA LongevityTech.Fund Alexandra Bause, PhD Apollo Health Ventures 5:30 PM - 7:00 PM Networking April 29th Applications of Longevity Medicine 8:30 AM - 8:55 AM Morning Networking 8:55 AM - 9:00 AM Watch now! Opening Remarks Dylan V. Livingston Founder and CEO, A4LI 9:00 AM - 9:35 AM Watch now! The Global Longevity Economy Moderator Michael Ringel JD, PhD COO, Life Biosciences Raiany Rommani Longevity Policy & E … General Partner at NFX Petr Sramek, MBA Co-Founder and Chairman, Longevitytech.fund Karl Pfleger, PhD Founder, Agingbiotech.info 2:55 PM - 3:00 PM Coffee Break 3:00 PM - 3:40 PM Watch now! Startup Stories — Paths to Funding Moderator Sonia Arrison Founder, 100 Plus Capital Mac Davis Founder and CEO, Minicircle Jasmine Smith CEO, RejuveAI Joe Betts-LaCroix CEO, Retro Biosciences 3:40 PM - 4:15 PM Watch now! Legal Perspectives in Longevity Science Moderator Thomas Zuber, JD Ma … he small business community, Kesselring received the 2022 SBA District Director Award for his work supporting small business owners across the country through SCORE and affiliated organizations, with a particular focus on helping businesses establish an online presence during the COVID-19 shutdown. He is also an alumnus of the Goldman Sachs 10,00
Tornado Therapeutics | MTEC MTEC Focus Areas Who we serve Solicitations Patents About Us Explore Join MTEC Log In Life Sciences / Companies Tornado Therapeutics Biopharmaceutical company focused on discovery and development of next-generation small-molecule mTOR inhibitors (rapalog analogues) with improved selectivity profiles intended to treat aging-related conditions and other indications. Pipeline includes multiple in‑licensed small molecules progressing through lead optimization, IND‑enabling studies and preclinical efficacy testing. Organizational capabilities include medicinal chemistry,
Tornado Therapeutics | Lifespan Research Institute Donate Login About Mission Board of Directors Scientific Advisory Board Team Annual Reports Contact Research Supported Projects Investments Publications Education Summer Scholars Post-Baccalaureate Host Lab Signup News Outlet Investor Network About Join Reports Advocacy Video Initiatives Engaging the Press Crowdfunding Sponsored Projects Advocacy Topics A4LI Resources Rejuvenation Roadmap Infographics Longevity Topics Find Longevity Events EARD Conference Archive Get Involved Donate Be a Lifespan Hero Hall of Heroes Join the Lifespan Alliance
The 9th ARDD: Longevity Biotechnology Is Gaining Prominence And Credibility In The Pharmaceutical Industry Sign Up For Newsletters Games Share a News Tip Featured Featured Breaking News White House Watch Daily Cover Stories 2026 Forbes World's Most Influential CMOs List Making It Their Way: Six TikTok Creators On Finding A High-Quality Content Strategy That Pays Off | Paid Program The Hidden Tax On Enterprise AI: 1 In 5 Workers Lose A Full Day Every Week | Paid Program Scaling AI Editorial Video Series Silicon & Steel Editorial Video Series Turning Pressure Into Progress For Your Smal … and Psychology team. In 2018, he worked as a publishing manager focusing on the proposal to launch Nature Aging and took over direction of the journal in March 2020. Some of the other talented scientists who will be involved in this workshop include Tornado Therapeutics CEO Joan Mannick , Human Longevity CEO Wei-Wu He , Gameto CEO Dina Radenkovic , and Hevolution Foundation CEO Mehmood Khan , to name a few. I have written about Dina and Joan as part of my ‘Women in Longevity’ … , and Sara Hagg . Day 5 : The last day of the event will kick-off with a poster award ceremony, followed by presentations on bringing geroscience into clinical practice, predicting mortality in old age, and quantifying age and rejuvenation. The final presentation will be made by Vera Gorbunova on the topic of mechanisms of longevity and epigenome stability. The event will wrap up after this – however, this is not all, there’s way more! The ARDD is Completely Non-Profit and ha … dsen did his medical training at the University of Copenhagen including a short scholarship investigating mitochondrial physiology. During medical school he founded his first company, Forsoegsperson.dk, which has grown to be the largest provider of volunteers for clinical trials in Denmark. After medical school he worked as a medical doctor in Denmark and Greenland before moving to basic science as a post doctoral fellow at the National Institute on Aging, NIH, in Baltimore. … Interventions section; He is an advisor to Deep Longevity, the Longevity Vision Fund and Vitexia; He has given invited presentations at top institutions (NIH, MIT, Harvard, NUS, Karolinska and others); and received several awards for his research. In addition, he has been organizing the Aging Research and Drug Discovery meeting. Daniela Bakula, P
11 anti-aging biotech companies leading longevity in 2026 Skip to content Search for: Suggested Topics: Categories Browse by resource or article category Knowledge hub Resources Biotech funding tracker Biotech deals tracker Biotech layoff tracker Biotech events 2026 List of biotech grants Biotech associations Categories News and Trends In-depth Best in Biotech Podcasts Top Pharma Strategy Opinion Expert Advice Sponsored Mending university and venture capital relations: is it possible to see eye-to-eye? Portugal: will the life science sector see upswing amid funding worries? Sectors Browse by s … nown as “Yamanaka factors”, named after Japanese stem cell researcher and Nobel Prize laureate Shinya Yamanaka – that can transform somatic cells into pluripotent stem cells, inducing changes in gene expression and cellular behavior. This effectively reverses or modifies the epigenetic markers associated with aging, rejuvenating cells and tissues, and potentially slowing down or reversing the effects of aging and age-related diseases (such as neurodegenerative conditions).&nb … formative medicines. Altos’ immediate focus when it launched was to fund its scientists and researchers to properly understand rejuvenation, such as how to tailor reprogramming to see if it can rejuvenate animals without killing them, and whether the process can be carried out using ordinary drugs instead of through genetic engineering. For a while after its launch, not much was known about the company’s activities. But, finally, in 2024, a paper was publish … onal strategy, combining the advantages of a biotech company, a venture capital fund, and an incubator. Since its inception, it has developed a pipeline of companies and therapies that can treat and prevent age-related diseases and lengthen healthspan. The anti-aging company believes that the future of medicine lies in approaching these diseases proactively, removing damage at a cellular level before a person becomes a patient. Each candidate in CambrianR … ($4.3 million) in financial support from the Wallonia region of Belgium to help fund the development costs of GF-1002 for the treatment of metabolic-associated steatohepatitis (MASH). More recently, the company raised £800,000 ($1.06 million) through a share subscription intended to advance its scientific programmes and strengthen its negotiating
LongBio Report 2025 | Alexander Tchernev | 12 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy
age1’s 2025 1st Annual Pharma Aging Report Card Subscribe Sign in age1’s 2025 1st Annual Pharma Aging Report Card Grading the giants on their race to extend human healthspan age1 and Soleil Wizman Jul 29, 2025 26 4 Share Only decades ago, aging research remained a niche curiosity sequestered to a handful of academic labs across the world. But long gone are the days when longevity was a fringe pursuit struggling for funding and mainstream attention. Today, top pharma companies are pouring millions into trials, partnerships, and acquisitions in the longevity space, signaling a fundamental shift … e brain tissue is still salvageable. On the investment front, the Roche Venture Fund committed $290 million in 2022 to Freenome , an SF-based company developing machine learning-enabled multiomics blood tests to detect colorectal and lung cancers at their earliest stages. And in 2023, Roche partnered with Alnylam Pharmaceuticals to commercialize zilebesiran, an RNAi therapeutic reducing liver angiotensinogen mRNA levels to lower blood pressure. Roche also recently acquired Ca … Smart Healthy Aging QuickFire Challenge , which invites Japan-based founders to submit promising science or technologies with the potential to increase healthy life expectancy. J&J committed $300,000 in grant funding, lab access, and mentorship to four startups. While J&J’s commitment to aging in the Asia Pacific region had long evaded the U.S., the New Jersey-based corporation has recently begun employing scientists to research aging and metabolism in its home countr … $80 million in exchange for an option to buy out the company at the time of IND application submission. Earlier transactions include AZ’s $1.8 billion acquisition of CinCor Pharma in 2023 , bringing in aldosterone-synthase inhibitor baxdrostat, now in Phase III alongside dapagliflozin, and a 2021 exclusive licence of Dogma Therapeutics’ first-in-class oral PCSK9-inhibitor program (advanced internally as AZD0780, Phase II). Thus, the British-Swedish multinational pharmaceutica … ost public venture into the aging space was its partnership with Alphabet to co-fund Calico, a biotechnology company aimed at understanding the underlying biology controlling aging. AbbVie partnered with Calico in 2014 and renewed the investment in 2018 and 2021 with an additional $500 million each. However, Calico has been shrouded in controvers
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Cambrian Bio | Pipeline About Science Pipeline Team Careers News & Publications Blogs Contact Therapeutics to treat and prevent today’s most debilitating chronic diseases Cambrian is developing a wide array of new therapeutics, each targeting a biological driver of aging. We work with top-tier academic institutions to create Cambrian Affiliate Companies (Affiliates) across the US and Europe. Pipeline Highlights View our full list of programs Cambrian is advancing multiple scientific inventions. Our approach is to develop interventions that treat specific diseases first, then utilize them a
Report: Cambrian Business Breakdown & Founding Story | Contrary Research Companies Reports Foundations & Frontiers Tech Trends Report Conversations About Powered by Discover Companies Reports Foundations & Frontiers Tech Trends Report Conversations Fellowship About Connect Email LinkedIn Twitter Subscribe Powered by © 2026 Contrary Research · All rights reserved Privacy Policy By navigating this website you agree to our privacy policy . Deny Accept Overview Memo Authors 1 Resources 7 Similar Companies 9 Share Cambrian Biotech Cambrian Bio is a biotech company with multiple programs … his collaboration ultimately led to an invitation to establish a new investment fund based in Germany. In 2016, Peyer co-founded Apollo Health Ventures , a fund dedicated to creating and investing in biotech companies developing therapies that target the mechanisms of aging. It was through Apollo that Peyer met Brunemeier. Brunemeier had begun a joint Ph.D. program at Scripps and Oxford studying the biochemistry of aging before leaving academia to launch new companies full-ti … stant depression. With a personal interest in slowing aging, Angermayer and his fund, Apeiron Investment Group , would go on to provide the financial foundation for Cambrian’s launch, anchoring the company’s $60 million raise as it emerged from stealth in 2021. As Cambrian expanded, James invited Juliette Han to join Cambrian as COO and CFO in 2020 . Han was a former mentor to James at McKinsey and before Cambrian, she was Chief of Staff at Two Sigma Investments, COO of peopl … 00 million in October 2021. The financing was co-led by Anthos Capital and SALT Fund, with existing investors such as Apeiron Investment Group (co-founder, Angermeyer’s fund), Future Ventures, and Moore Capital also investing in the round. Several of Cambrian’s portfolio companies have raised capital as well. As of November 2025, Amplifier Therapeutics has raised a total of $33.3 million , all of which came from its Series A round led by Future Ventures and RA Capital Managem … onomists at MIT proposed that biotech productivity could improve when companies apply principles of portfolio theory. They suggested that isolating scientific bets into independent entities reduces correlated risk and creates the opportunity to raise program-level debt. This is a feature that has enabled Bridge Bio to achieve three FDA approvals
XBRL Viewer Please enable JavaScript to use the EDGAR Inline XBRL Viewer.